PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcgenoBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Genomics
 
BMC Genomics. 2009; 10: 66.
Published online Feb 5, 2009. doi:  10.1186/1471-2164-10-66
PMCID: PMC2647556
Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice
Claudia Prinzen,1 Dietrich Trümbach,2 Wolfgang Wurst,2 Kristina Endres,1 Rolf Postina,1 and Falk Fahrenholzcorresponding author1
1Johannes Gutenberg-University, Institute of Biochemistry, Mainz, Johann-Joachim-Becherweg 30, 55128 Mainz, Germany
2Helmholtz Zentrum München – German Research Center for Environmental Health, Institute for Developmental Genetics, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany
corresponding authorCorresponding author.
Claudia Prinzen: prinzen/at/uni-mainz.de; Dietrich Trümbach: dietrich.truembach/at/helmholtz-muenchen.de; Wolfgang Wurst: wurst/at/helmholtz-muenchen.de; Kristina Endres: endres.uni-mainz/at/email.de; Rolf Postina: postina/at/uni-mainz.de; Falk Fahrenholz: fahrenho/at/uni-mainz.de
Received June 19, 2008; Accepted February 5, 2009.
Abstract
Background
In a transgenic mouse model of Alzheimer disease (AD), cleavage of the amyloid precursor protein (APP) by the α-secretase ADAM10 prevented amyloid plaque formation, and alleviated cognitive deficits. Furthermore, ADAM10 overexpression increased the cortical synaptogenesis. These results suggest that upregulation of ADAM10 in the brain has beneficial effects on AD pathology.
Results
To assess the influence of ADAM10 on the gene expression profile in the brain, we performed a microarray analysis using RNA isolated from brains of five months old mice overexpressing either the α-secretase ADAM10, or a dominant-negative mutant (dn) of this enzyme. As compared to non-transgenic wild-type mice, in ADAM10 transgenic mice 355 genes, and in dnADAM10 mice 143 genes were found to be differentially expressed. A higher number of genes was differentially regulated in double-transgenic mouse strains additionally expressing the human APP[V717I] mutant.
Overexpression of proteolytically active ADAM10 affected several physiological pathways, such as cell communication, nervous system development, neuron projection as well as synaptic transmission. Although ADAM10 has been implicated in Notch and β-catenin signaling, no significant changes in the respective target genes were observed in adult ADAM10 transgenic mice.
Real-time RT-PCR confirmed a downregulation of genes coding for the inflammation-associated proteins S100a8 and S100a9 induced by moderate ADAM10 overexpression. Overexpression of the dominant-negative form dnADAM10 led to a significant increase in the expression of the fatty acid-binding protein Fabp7, which also has been found in higher amounts in brains of Down syndrome patients.
Conclusion
In general, there was only a moderate alteration of gene expression in ADAM10 overexpressing mice. Genes coding for pro-inflammatory or pro-apoptotic proteins were not over-represented among differentially regulated genes. Even a decrease of inflammation markers was observed. These results are further supportive for the strategy to treat AD by increasing the α-secretase activity.
Articles from BMC Genomics are provided here courtesy of
BioMed Central